Marvin L. Woodall Named CEO of
Cardiovascular Research Foundation
Man Who Pioneered Innovative Coronary Stent Technology
Takes on New Leadership
Role at Organization
New York – August 9, 2006 – Marvin L. Woodall, a long-standing member of the Board of Directors of the Cardiovascular Research Foundation (CRF), was named the Chief Executive Officer (CEO) of the organization effective immediately. The position of CEO is newly created in an effort to both manage the tremendous growth experienced by CRF over the past several years as well as to lead the Foundation in new endeavors in the future.
"For nearly two decades, Marv Woodall has been a highly respected leader in the interventional vascular medicine community," said CRF Chairman Martin B. Leon, MD, who made the announcement. "I have no doubt that he is the right person to provide the strong leadership necessary to take CRF into the future."
From 1988 until 1996, Mr. Woodall was the President of Johnson & Johnson Interventional Systems. At J&J, he led the team responsible for developing the original PALMAZ-SCHATZ® Coronary Stent, which was designated as "the most important new medical device in the past 15 years" in a survey of medical device company CEOs in 1996. In 1995, he initiated the original drug-eluting stent (DES) research that led to the first FDA-approved DES. Subsequently, Mr. Woodall served as Chairman of the Board of Trustees of Lehigh Valley Hospital and Health Network. He is currently on the boards of several physician and healthcare-related organizations.
"For 15 years, CRF has played a pivotal role in advancing the field of interventional cardiology," said Mr. Woodall. "In the future, we will accelerate and expand our educational, research, and academic programs for the interventional cardiovascular community."
Dr. Leon and Mr. Woodall both noted key milestones at CRF that have led to the organization's rapid growth. These included a partnership with Columbia University Medical Center in 2004 and the opening of CRF's pre-clinical facility, the Jack H. Skirball Center for Cardiovascular Research, in 2005.
About CRF
The Cardiovascular Research Foundation is dedicated to research and education in the broad subspecialty of interventional cardiology and endovascular medicine. By establishing the safe use of new technologies and pharmacologic agents, CRF has for more than 15 years played a major role in the remarkable advances in survival and quality of life being realized for patients with cardiovascular disease. CRF's annual Transcatheter Cardiovascular Therapeutics (TCT) meeting is the world's premier gathering where the latest trends, research findings and techniques in interventional vascular medicine are disseminated to practicing physicians from around the world. In 2006, TCT takes place October 22-27 in Washington, DC.
Source: Cardiovascular Research Foundation |
